After over 25 years as an intellectual property (IP) attorney, Jane Remillard, Nelson Mullins patents and biotechnology IP senior partner, is well-versed in navigating drug development and antibody patent law. In this episode, Remillard speaks with moderator Nimish Gera, Mythic Therapeutics vice president of biologics, about the intersection between science and law, the primary steps recommended to patent a scientific discovery, and how the antibody IP landscape has evolved in recent years. She also talks about the importance of implementing a strategy regarding the number and types of antibody patents filed, her advice to anyone considering a career in IP law, and what to expect from the industry moving forward.  Links from this episode:   Nelson Mullins Mythic Therapeutics